Dominique Sainte-Marie, Nicolas Fasel, Pierre Couppié, Ricardo Martin, Frédéric Schütz, Florence Robert-Gangneux, Antoine Bertolotti, Catherine Ronet, Mary-Anne Hartley, Marine Ginouves, Ghislaine Prévot, Francine Pratlong, J. Dufour, Eliane Bourreau, Jean-Pierre Gangneux, Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Université de Lausanne = University of Lausanne (UNIL), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Parasitologie-Mycologie [Rennes], Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service de Dermatologie et Vénérologie, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Centre National de Référence des Leishmanioses [CHRU Montpellier] (CNR-L), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Swiss Institute of Bioinformatics [Lausanne] (SIB), OPP1056785, Bill and Melinda Gates Foundation (Grand Challenges Explorations, Pierre Mercier Foundation (to C. R.), the Guiana Pasteur Institute–, 3100A0-116665/1, the French Ministry for Higher Education and Research, We thank Stephen Beverley (Washington University, St Louis, Missouri) and Jean-Claude Dujardin (Institute of Tropical Medecine, Antwerp, Belgium), for discussions and communications of unpublished data, the Pôle Intégré de Recherche Clinique of the Pasteur Institute, notably Nathalie Jolly, who facilitated the ethical approval, and Prof Pascal Launois, for helpful discussion, and Stéphane Simon, Loic Taglignani, and Patrick Lami, for their contribution regarding the Leishmania parasite cultures., Université de Lausanne (UNIL), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], and Université de Montpellier (UM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
International audience; Treatment failure and symptomatic relapse are major concerns in American tegumentary leishmaniasis (TL). Such complications are seen frequently in Leishmania guyanensis infections, in which patients respond variously to first-line antileishmanials and are more prone to develop chronic cutaneous leishmaniasis. The factors underlying this pathology, however, are unknown. Recently, we reported that a double-stranded RNA virus, Leishmania RNA virus 1 (LRV1), nested within L. guyanensis parasites is able to exacerbate experimental murine leishmaniasis by inducing a hyperinflammatory response. This report investigates the prevalence of LRV1 in human L. guyanensis infection and its effect on treatment efficacy, as well as its correlation to symptomatic relapses after the completion of first-line treatment. In our cohort of 75 patients with a diagnosis of primary localized American TL, the prevalence of LRV1-positive L. guyanensis infection was elevated to 58%. All patients infected with LRV1-negative L. guyanensis were cured after 1 dose (22 of 31 [71%]) or 2 doses (31 of 31 [100%]) of pentamidine. In contrast, 12 of 44 LRV1-positive patients (27%) presented with persistent infection and symptomatic relapse that required extended therapy and the use of second-line drugs. Finally, LRV1 presence was associated with a significant increase in levels of intra-lesional inflammatory markers. In conclusion, LRV1 status in L. guyanensis infection is significantly predictive (P = .0009) of first-line treatment failure and symptomatic relapse and has the potential to guide therapeutic choices in American TL.